Clinical Trials | December 30, 2025
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
The study met its primary endpoint with flying colors
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Adverse events were consistent with valbenazine’s established safety profile
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated
